A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
Recruiting · Phase 3 · NCT07071519
Conditions: Ulcerative Colitis
At a glance
- Research payments reported, 2025
- $14,042
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 120
About the trial
- Sponsor
- AbbVie
- Tested
- Risankizumab (drug), Risankizumab (drug)
- Dates
- Started 2025-07-28; completion 2034-07
- Results posted
- Not yet
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how Risankizumab moves through the body as well as how safe and effective it is in treating pediatric participants with moderate to severely active UC. Adverse events and change in disease activity will be assessed. Risankizumab is an approved medication for moderate to severe UC in multiple countries and is being developed for the treatment of UC in pediatrics. This study is comprised of 3 cohorts that may participate in 3 substudies (SS). Cohort 1 will enroll participants with ages from 6 to less than 18 y…
From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $14,042 in research payments for this study in 2025 (1 payments).
Products named: Skyrizi
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children S Center for Digestive $14,042
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.